Table 1.
Clinical characteristics of 98 patients with bone metastatic prostate cancer from whom paired metastatic and primary tumor tissue were available.
| Median (25th; 75th Percentiles) |
|
|---|---|
| Age diagnosis (yrs.) | 69 (65; 75) |
| Age metastasis surgery (yrs.) | 73 (68; 78) |
| Serum PSA diagnosis (ng/mL) | 78 (30; 440) |
| Serum PSA metastasis surgery (ng/mL) | 140 (32; 470) |
| Time btw sampling of primary tumor and metastasis tissue biopsies (yrs.) | 1.9 (0.75; 4.6) |
| ISUP grade at diagnosis: | N |
| 2 | 3 (3%) |
| 3 | 31 (32%) |
| 4 | 34 (35%) |
| 5 | 30 (31%) |
| Castration therapy a: | N |
| None (hormone-naïve) | 13 (13%) |
| Short-term b | 4 (4%) |
| CRPC c | 81 (83%) |
| Treatment for CRPC: | N |
| Bicalutamide | 46 (49%) |
| Chemotherapy | 20 (20%) |
| Abiraterone acetate | 10 (10%) |
| Enzalutamide | 4 (4%) |
| Ra223 | 3 (3%) |
| Zoledronic acid/Denosumab | 2 (2%) |
Continuous variables given as median (25th; 75th percentiles). a Castration therapies given prior to collection of metastasis tissue samples included surgical ablation, LHRH/GnRH agonist therapy or bicalutamide treatment. b Castration therapy for 1–17 days before metastasis tissue sampling. c Defined to have castration-resistant prostate cancer (CRPC) due to disease progression during castration therapy. PSA, prostate specific antigen; ISUP, International Society of Urological Pathology.